Physician profile
Gregory R Delost
NPI 1073995791
$383,003.37
in general payments reported to CMS, 2019-2025
30 companies · $164K in 2025
The $164K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $185 · 2020: $766 · 2021: $542 · 2022: $21K · 2023: $63K · 2024: $133K · 2025: $164K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $287K · Consulting Fee: $30K · Honoraria: $16K · Travel and Lodging: $15K · Food and Beverage: $13K · Education: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $286,549.01 |
| Consulting Fee | $29,662.50 |
| Honoraria | $16,250.00 |
| Travel and Lodging | $14,556.40 |
| Food and Beverage | $12,886.03 |
| Education | $345.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $194,821.46 | 2022-2025 | Tremfya, Simponi Aria, Simponi |
| Incyte Corporation | $104,941.78 | 2022-2025 | Opzelura, Opzelura |
| Janssen Scientific Affairs, LLC | $26,334.55 | 2022-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $23,173.53 | 2024-2025 | Zoryve |
| Lnhc, INC | $16,521.81 | 2025 | Zelsuvmi |
| Genzyme Corporation | $12,309.18 | 2020-2025 | |
| Abbvie INC. | $1,617.42 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Lilly USA, LLC | $484.03 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Ucb, INC. | $475.83 | 2020-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $470.58 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Pfizer INC. | $296.28 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $291.38 | 2019-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $186.59 | 2020-2025 | |
| Dermavant Sciences, INC. | $182.23 | 2023-2024 | Vtama |
| Leo Pharma INC. | $162.28 | 2022-2025 | Adbry, Anzupgo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $127.79 | 2020-2025 | Otezla, Otezla |
| Vyne Pharmaceuticals INC. | $127.09 | 2020 | |
| Novartis Pharmaceuticals Corporation | $107.98 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $70.95 | 2021-2023 | Ilumya, Odomzo, Blu-U |
| Stryker Corporation | $57.09 | 2025 | Clottriever Bold Catheter |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.31 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Regeneron Pharmaceuticals, INC. | $45.00 | 2019 | |
| Almirall LLC | $28.41 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $26.51 | 2023 | |
| Pierre Fabre Pharmaceuticals, INC. | $19.87 | 2025 | Hemangeol |
| Biofrontera INC. | $18.67 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $15.47 | 2021 | |
| Allergan, INC. | $14.44 | 2019 | |
| Strata Skin Sciences, INC. | $14.08 | 2024 | Xtrac |
| Dermira, INC. | $13.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Delost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.